SCHEMBL1998727

SCHEMBL1998727

O=Cc1c(F)c(F)c(O)c(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 1/20 0.36
ERN1 O75460 8/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966833 0.86 PADI4 (0.34) PADI4ERN1
SCHEMBL809345 0.84 VCP (0.33)
SCHEMBL419449 0.81 VCP (0.38)
SCHEMBL1808857 0.78 VCP (0.36)
SCHEMBL29933309 0.78 ERN1 (0.37) ERN1
SCHEMBL22042201 0.77 MEN1 (0.32)
SCHEMBL23360936 0.76 MEN1 (0.36) PADI4ERN1
SCHEMBL24834495 0.75
SCHEMBL1808693 0.74 MEN1 (0.35)
SCHEMBL1809301 0.74 VCP (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024181874-A1 METHOD FOR THE PREPARATION OF RHODOL DERIVATIVES POSSESSING THREE FLUORINE SUBSTITUENTS IN POSITIONS 1, 2 AND 4 AND COMPOUNDS OBTAINED BY THIS METHOD Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) 2024-09-06 WO claimed
US-12595275-B2 Fluorine-containing compound and anti-cancer medical use thereof ASCENTAWITS PHARMACEUTICALS, LTD. (CN) 2026-04-07 US disclosed
EP-3971194-B1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF ASCENTAWITS PHARMACEUTICALS LTD (CN) 2025-12-03 EP disclosed
EP-4598933-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF Allorion Therapeutics Inc (US) 2025-08-13 EP disclosed
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 CN disclosed
CN-118834240-A Fluorine-containing compound and anticancer medical application 深圳艾欣达伟医药科技有限公司 2024-10-25 CN disclosed
WO-2024181874-A1 METHOD FOR THE PREPARATION OF RHODOL DERIVATIVES POSSESSING THREE FLUORINE SUBSTITUENTS IN POSITIONS 1, 2 AND 4 AND COMPOUNDS OBTAINED BY THIS METHOD Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) 2024-09-06 WO disclosed
CN-113853379-B Fluorine-containing compound and anticancer medical application 深圳艾欣达伟医药科技有限公司 2024-04-30 CN disclosed
WO-2024078392-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) 2024-04-18 WO disclosed
US-20220119429-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF ASCENTAWITS PHARMACEUTICALS, LTD. (CN) 2022-04-21 US disclosed
WO-2020228685-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF 深圳艾欣达伟医药科技有限公司 2020-11-19 WO disclosed
US-9984878-B2 Resist under layer film composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-05-29 US disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 US disclosed
US-20160342088-A1 RESIST UNDER LAYER FILM COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-07-09 US disclosed
WO-2013086131-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-06-13 WO disclosed
US-7964878-B2 Light emitting polymer devices using self-assembled monolayer structures HCF PARTNERS, LP (US) 2011-06-21 US disclosed
US-20100134052-A1 Light Emitting Polymer Devices Using Self-Assembled Monolayer Structures HCF PARTNERS, L.P. (US) 2010-06-03 US disclosed
WO-2006116584-A2 LIGHT EMITTING POLYMER DEVICES USING SELF-ASSEMBLED MONOLAYER STRUCTURES DYNAMIC ORGANIC LIGHT, INC. (US) 2006-11-02 WO disclosed
US-4717760-A HEAT AND WATER RESISTANCE WHEN CURED THE DOW CHEMICAL COMPANY (US) 1988-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595275-B2 Fluorine-containing compound and anti-cancer medical use thereof BCOR, BCL6, CCR6 PADI4 4000/4885ERN1 2232/4885
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A HAVCR2, HDLBP, HSP90B1 PADI4 1811/4885ERN1 1739/4885
US-20220119429-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF FLI1, FOLR2, FOLR1 PADI4 3019/4885ERN1 3306/4885
US-20100134052-A1 Light Emitting Polymer Devices Using Self-Assembled Monolayer Structures CLTB, CYBA, CLTA PADI4 900/4885ERN1 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.